DOI:
10.1055/s-00034915
Onkologische Welt
LinksClose Window
References
Hofheinz RD. et al
Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2-positive resectable esophagogastric adenocarcinoma: Final results of the PETRARCA multicenter randomized phase II trial of the AIO..
ASCO 2020 Abstract 4502
We do not assume any responsibility for the contents of the web pages of other providers.